Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) Director Nassim Usman sold 20,000 shares of the business's stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $14.13, for a total transaction of $282,600.00. Following the sale, the director now directly owns 1,636 shares in the company, valued at $23,116.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Gyre Therapeutics Stock Performance
Shares of GYRE opened at $14.10 on Friday. Gyre Therapeutics, Inc. has a 1-year low of $3.13 and a 1-year high of $30.40. The firm's fifty day moving average is $17.68.
About Gyre Therapeutics
(
Get Free Report)
Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
